These data are evidence that increased APP gene dose in DS, along with increased levels of APP and its products, including β-CTF, acts to induce Rab5 hyperactivation and reduce retrograde transport of neurotrophin signaling, thus linking APP gene dose to neurodegeneration. The gene discussed is RAB5A; the disease is Dravet syndrome.